- Home
- CRT vs PSNL Comparison
CRT vs PSNL Comparison
Compare CRT & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- PSNL
- Stock Information
- Founded
- CRT 1991
- PSNL 2011
- Country
- CRT United States
- PSNL United States
- Employees
- CRT N/A
- PSNL N/A
- Industry
- CRT Oil & Gas Production
- PSNL Medical Specialities
- Sector
- CRT Energy
- PSNL Health Care
- Exchange
- CRT Nasdaq
- PSNL Nasdaq
- Market Cap
- CRT 65.1M
- PSNL 576.8M
- IPO Year
- CRT 1992
- PSNL 2019
- Fundamental
- Price
- CRT $9.70
- PSNL $7.32
- Analyst Decision
- CRT
- PSNL Strong Buy
- Analyst Count
- CRT 0
- PSNL 5
- Target Price
- CRT N/A
- PSNL $8.00
- AVG Volume (30 Days)
- CRT 22.2K
- PSNL 1.7M
- Earning Date
- CRT 01-01-0001
- PSNL 08-06-2025
- Dividend Yield
- CRT 9.19%
- PSNL N/A
- EPS Growth
- CRT N/A
- PSNL N/A
- EPS
- CRT 0.99
- PSNL N/A
- Revenue
- CRT $6,834,116.00
- PSNL $85,694,000.00
- Revenue This Year
- CRT N/A
- PSNL $0.45
- Revenue Next Year
- CRT N/A
- PSNL $25.75
- P/E Ratio
- CRT $9.81
- PSNL N/A
- Revenue Growth
- CRT N/A
- PSNL 15.57
- 52 Week Low
- CRT $8.88
- PSNL $1.19
- 52 Week High
- CRT $13.31
- PSNL $7.73
- Technical
- Relative Strength Index (RSI)
- CRT 41.51
- PSNL 79.86
- Support Level
- CRT $9.74
- PSNL $6.27
- Resistance Level
- CRT $9.99
- PSNL $7.03
- Average True Range (ATR)
- CRT 0.18
- PSNL 0.49
- MACD
- CRT 0.00
- PSNL 0.10
- Stochastic Oscillator
- CRT 8.11
- PSNL 94.69
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.